| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Mifamurtide |
| Brand | Mepact® |
| Indication | For the treatment of osteosarcoma. |
| Assessment Process | |
| Rapid review commissioned | 22/06/2010 |
| Rapid review completed | 13/07/2010 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
A formal PEA is required to demonstrate value for money prior to reimbursement.
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.